Hannah Slater


Relugolix May Become New Standard of Care for Advanced Prostate Cancer

June 01, 2020

Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer.

FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia

May 01, 2020

The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study.

FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors

April 07, 2020

The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.